Sushmita Panda

The mixed results from the Phase III ENERGY 3 trial raises questions around the regulatory path forward for the enzyme therapy.

Positive Phase III hypochondroplasia data could help BioMarin expand the Voxzogo franchise beyond achondroplasia as competition in skeletal dysplasias intensifies.

Biogen and Denali's decision to discontinue BIIB122 in idiopathic Parkinson's disease after a failed Phase IIb study shifts focus toward genetically defined LRRK2 patient subsets and other late-stage neuroscience pipeline catalysts.

Datroway's first-line TNBC approval strengthens competition in the TROP2 ADC market as rivals including Gilead advance therapies into earlier treatment settings.

While early data for VERVE-102 mark another step in Lilly's push into cardiovascular gene editing, analysts question the need for a one-and-done therapy to lower LDL-C given existing treatment options.

The company presented new data to strengthen the case for direct cccDNA targeting in chronic hepatitis B, an area long viewed as one of the field's central scientific challenges.

Imfinzi's new NMIBC approval strengthens AstraZeneca's position in bladder cancer as the company expands the asset beyond its established indications.

Encouraging efficacy signals and a manageable safety profile have prompted BioNTech and Bristol Myers Squibb to push pumitamig deeper into late-stage development.

Attention is now shifting to how regulators, physicians and investors interpret malignancy findings that overshadowed an otherwise successful readout.

As Livdelzi gains traction in the second-line PBC market, the IDEAL study offers Gilead an opportunity to strengthen the drug's regulatory and commercial positioning beyond its original approval population.